Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
antibiotic
continuous infusion
intensive care unit
outpatient parenteral antimicrobial therapy
stability
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
09
03
2022
revised:
24
03
2022
accepted:
26
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
The use of continuous infusion to improve the therapeutic efficacy of time-dependent antibiotics has been demonstrated. There is still a lack of data to safely perform these continuous infusions. The objectives in this study were to evaluate the stability by using stability-indicating methods (High-Performance Liquid Chromatography) of 16 antibiotics in concentrated solutions, especially for administration in intensive care units and solutions in elastomeric diffusers at 37 °C for outpatient parenteral antimicrobial therapy. The solutions were considered stable if the percentage of the drug was ≥90%, and the colour and clearness remained unchanged. In syringes, the stability data vary from 4 to 8 h (h) for meropenem in Dextrose 5% (D5W) and Normal Saline (NS), respectively, 6 h for cefotaxime, 12 h for cefoxitin, and 24 h for aztreonam, cefazolin, cefepime, cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam in NS and D5W, and in water for injection for cloxacillin. A stability period of 48 h has been validated for vancomycin (D5W), aztreonam, and piperacillin/tazobactam. Cefoxitin, cefazolin, cefepime, cefotaxime, cloxacillin, and piperacillin are unstable for diffuser administration. In diffusers, stability times vary from 6 h for cefiderocol, 8 h for ceftazidime, 12 h for ceftazidime/avibactam and ceftolozane/tazobactam (NS), 24 h for temocillin (NS) and piperacillin/tazobactam (D5W), up to 48 h for aztreonam and vancomycin. Solutions stored at 37 °C are less stable and allow the administration of seven antibiotics using diffusers.
Identifiants
pubmed: 35453211
pii: antibiotics11040458
doi: 10.3390/antibiotics11040458
pmc: PMC9030478
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Biomed Chromatogr. 2019 Apr;33(4):e4471
pubmed: 30549056
Antimicrob Agents Chemother. 2007 Sep;51(9):3449-51
pubmed: 17576831
Analyst. 1984 Sep;109(9):1209-12
pubmed: 6507879
Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):155-170
pubmed: 29027128
Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91
pubmed: 26974879
Ann Pharm Fr. 2011 Jul;69(4):221-31
pubmed: 21840442
Crit Care Med. 2006 Feb;34(2):344-53
pubmed: 16424713
Am J Hosp Pharm. 1989 Jul;46(7):1408-12
pubmed: 2667354
Eur J Hosp Pharm. 2020 Mar;27(e1):e53-e57
pubmed: 32296506
J Antimicrob Chemother. 2008 Feb;61(2):382-8
pubmed: 18070831
Eur J Hosp Pharm. 2022 Jul;29(4):212-216
pubmed: 32978220
Infect Dis Now. 2020 Jun 20;51(1):14-38
pubmed: 32574696
J Antimicrob Chemother. 2017 Sep 1;72(9):2613-2615
pubmed: 28605490
J Antimicrob Chemother. 2015 Apr;70(4):965-70
pubmed: 25538169
Med Mal Infect. 2016 Jul;46(5):242-68
pubmed: 27112521
Eur J Hosp Pharm. 2021 Aug 18;:
pubmed: 34407976
Crit Care Med. 2020 Jun;48(6):912-918
pubmed: 32317590
Eur J Hosp Pharm. 2020 Mar;27(2):90-94
pubmed: 32153771
Eur J Hosp Pharm. 2021 Dec 3;:
pubmed: 34862256
Clin Infect Dis. 2019 Jan 1;68(1):e1-e35
pubmed: 30423035
Home Healthc Now. 2017 Jan;35(1):10-18
pubmed: 27922994
Infect Dis Now. 2020 Oct 22;51(1):39-49
pubmed: 33576336
Am J Health Syst Pharm. 1995 Nov 15;52(22):2560-4
pubmed: 8590240
J Antimicrob Chemother. 2018 Sep 1;73(9):2540-2545
pubmed: 29982449
Antimicrob Agents Chemother. 2002 Aug;46(8):2327-32
pubmed: 12121900